VitaSelect™ — sourcing & qualification
HLA-screened, consent-governed donor registry. Three homozygous donors currently cover 61% of the global HLA-DRB1 distribution we target.
One donation · up to 500 dosesClinical-stage · Cell & gene therapeutics
Living medicines,
engineered cell by cell.
CellVita Biotech engineers allogeneic cell therapies for oncology, immunology and regenerative medicine — from a single qualified donor to a cryopreserved dose that reaches the patient in 72 hours.
0Active programmes
0In clinical stage
0Patients treated to date
0Scientists & engineers
GMP-grade batch · CVT-101-201
Phase II interim · Q3 2027
VitaSelect™ — potency-qualified master cell banks
Every lot released against 41 in-process and 12 release assays before it leaves Basel.
98.4%
Median post-thaw viability at dose
Inspected, licensed & audited
- FDA IND cleared
- EMA CTA granted
- EU GMP Annex 1
- ISO 13485
- ISO 14001
Universitätsklinik Basel
Charité Berlin
Dana-Farber Consortium
National Cancer Centre Singapore
Karolinska Trial Unit
King's College Haematology
Mayo Regenerative Group
Riken iPSC Network
The CellVita platform
Three proprietary steps between a donor and a dose.
Our platform replaces donor variability and open processing with a qualified, closed and instrumented chain — so an off-the-shelf dose behaves like a batch, not an experiment.
VitaExpand™ — closed perfusion bioreactors
3D perfusion culture with in-line metabolite sensing. Fully closed from thaw to fill-finish, so no operator touches the product.
20× yield · one fifth of the cleanroom footprintVitaDeliver™ — targeted, scaffolded delivery
Injectable hydrogel scaffolds that anchor cells at the site of injury and hold a local therapeutic window instead of a systemic burst.
14-day local retention in vivoResearch & development pipeline
Eleven programmes. Four already in patients.
A deliberately narrow modality set — NK, CAR-NK, MSC and iPSC-derived cells — taken deep in four therapeutic areas instead of wide across twenty.
CVT-101
Phase II
Allogeneic NK cell therapy
Next milestone: interim ORR readout, Q3 2027
CVT-104
Phase II
MSC therapy for steroid-refractory GvHD
Next milestone: day-28 response data, Q1 2027
CVT-207
Phase I
TCR-engineered T cells for NSCLC
Next milestone: RP2D selection, Q4 2027
CVT-211
Phase I
CAR-NK for multiple myeloma
Next milestone: safety review committee, Q2 2027
CVT-305
Phase I/II
Chondrocyte implant for knee OA
Next milestone: 52-week WOMAC analysis, Q2 2028
CVT-312
Preclinical
MSC therapy for diabetic foot ulcer
Next milestone: IND-enabling package, Q2 2028
CVT-401
Preclinical
iPSC-derived dopaminergic cells
Next milestone: IND submission, Q2 2028
CVT-408
Discovery
Encapsulated islet cell therapy
Next milestone: candidate selection, Q1 2028
CVT-502
Preclinical
Islet-like clusters for type 1 diabetes
Next milestone: large-animal efficacy, Q3 2028
CVT-509
Discovery
Hepatocyte-like cells for metabolic liver disease
Next milestone: in-vivo proof of concept, Q4 2028
CVT-118
Preclinical
Regulatory NK cells for solid-organ tolerance
Next milestone: IND-enabling package start, Q4 2027
Programme distribution across the lifecycle
11 programmes · 4 in the clinic · first commercial launch targeted 2030
- Discovery · 2
- Preclinical · 4
- Phase I · 2
- Phase I/II · 1
- Phase II · 2
Product categories
Six franchises, one manufacturing backbone.
Investigational cell products and the process technology that makes them reproducible — all produced in the same closed, instrumented platform.
Oncology
ImmunoVita™
Allogeneic NK and CAR-NK cell products engineered for off-the-shelf use in relapsed haematological malignancies.
- 3 homozygous donor lines
- Cryopreserved, dose-ready vials
- 72-hour release-to-patient
Regenerative
RegeneraVita™
Mesenchymal stromal cell products for orthopaedic repair, chronic wounds and inflammatory tissue injury.
- Bone-marrow derived MSC
- VitaDeliver™ hydrogel format
- 24-month stability data
Neurology
NeuroVita™
iPSC-derived dopaminergic and cortical cell populations for neurodegenerative and CNS repair indications.
- Clinical-grade iPSC line
- Stereotactic delivery protocol
- >92% purity at release
Cardiology
CardioVita™
Cardiac progenitor cell sheets and injectable populations for ischaemic cardiomyopathy after myocardial infarction.
- Cell-sheet, suture-free format
- MRI-guided placement
- Partner-led Phase I planned
Dermatology
VitaDerm™
Autologous keratinocyte and fibroblast suspensions for complex burns, chronic ulcers and reconstructive surgery.
- Point-of-care harvest kit
- Spray-on application
- Hospital-exemption use in EU
Platform
VitaCore™
The enabling franchise: media, closed bioreactors, cryoprotectant formulations and QC assay kits sold to other developers.
- Xeno-free culture media
- Single-use closed bioreactor
- Alliance programme for developers
Clinical trials
Eleven studies running across four clinical programmes.
Sponsor-initiated and partner-led trials across 34 sites in nine countries. Every protocol is registered and every interim analysis is pre-specified.
0Active clinical studies
0Patients enrolled across the programme
0Investigational sites worldwide
0Countries with active enrolment
CVT-101-201 · NCT-2214-887
Recruiting
Allogeneic NK cells in relapsed or refractory AML
Phase II · randomised, open-label
- Sites
- 34 · US, DE, CH, JP
- Endpoint
- Overall response rate at day 100
- Cohort
- 142 patients planned
CVT-104-203 · NCT-2214-903
Recruiting
MSC therapy in steroid-refractory acute GvHD
Phase II · single-arm, with historical control
- Sites
- 21 · DE, FR, UK, SG
- Endpoint
- Overall response at day 28
- Cohort
- 96 patients planned
CVT-207-101 · NCT-2215-014
Enrolment complete
TCR-engineered T cells in advanced NSCLC
Phase I · dose escalation with expansion cohort
- Sites
- 8 · US, CH
- Endpoint
- Safety, RP2D, preliminary objective response
- Cohort
- 48 patients dosed
CVT-305-105 · NCT-2216-221
Active, not recruiting
Chondrocyte implant in moderate knee osteoarthritis
Phase I/II · randomised, double-blind, sham-controlled
- Sites
- 12 · AU, CH, UK
- Endpoint
- WOMAC pain change at 52 weeks
- Cohort
- 120 patients randomised
Trial design
Designed around the patient who has run out of options.
- Off-the-shelf logistics. No apheresis, no bridging chemotherapy and no vein-to-vein wait — a frozen dose is shipped to the site in 72 hours.
- Pre-specified interim analyses. Every Phase II has a documented futility boundary so resources move to what works.
- Access built in. Sites in low- and middle-income countries are included in the protocol, not added after approval.
- Published either way. Negative and positive readouts are registered and summarised within six months.
Sustainability & responsibility
Cell therapy is a heavy industry. We run it like a light one.
A single dose of advanced therapy can carry a 40-litre single-use plastic footprint and a −80 °C cold chain. Our 2032 roadmap takes both head-on — measured, audited and reported annually.
Scope 1 and 2 emissions are third-party verified under ISO 14064; the Basel, Boston and Singapore facilities all operate to ISO 14001.
0Renewable electricity across all three sitesAchieved 2025 · PPA-backed
0Single-use plastic removed from the process trainBaseline 2021 · independently audited
0Process water recycled at the Basel campusClosed-loop WFI recovery
0Target year for net-zero Scope 1 & 2 emissionsSBTi-aligned pathway
Greener labs, certified
All Basel laboratories hold My Green Lab certification; the Boston site is targeting the same by 2028, including solvent recovery and ultra-low freezer consolidation.
Cold-chain without the deep freeze
Dry-ship formulations validated at −20 °C where the science allows, cutting shipping energy per dose and making distribution to warmer climates viable.
Consent-led donor programme
Donors are recruited through an independent ethics framework with ongoing consent, benefit-sharing and publication rights — reviewed annually by an external panel.
Investor relations
Patient capital for the decade cell therapy becomes routine.
We build our own manufacturing rather than rent it. That is slower in year one and substantially cheaper at commercial scale — and it is why the next twelve months matter more than the last five.
Upcoming catalysts
- Q1 2027CVT-104 day-28 response data, Phase II
- Q3 2027CVT-101 interim overall response rate, Phase II
- Jan 2028J.P. Morgan Healthcare Conference — investor meetings
- Jun 2028CellVita R&D Day, Basel — manufacturing tour and platform deep dive
NASDAQ: CVBT
CellVita Biotech AG
$41.86
+1.84% today
Cash & equivalents€612M
RunwayInto H2 2030
Raised to date€412M
GMP facilities3 · Basel, Boston, Singapore
Shares outstanding58.4M
Illustrative figures for template demonstration only. Nothing on this page is an offer to sell or a solicitation to buy securities, and past performance is not a guide to future results.